J 2018

Survival of syngeneic and allogeneic iPSC–derived neural precursors after spinal grafting in minipigs

STRNADEL, Jan, Cassiano CARROMEU, Cedric BARDY, Michael NAVARRO, Oleksandr PLATOSHYN et. al.

Basic information

Original name

Survival of syngeneic and allogeneic iPSC–derived neural precursors after spinal grafting in minipigs

Authors

STRNADEL, Jan (840 United States of America), Cassiano CARROMEU (840 United States of America), Cedric BARDY (840 United States of America), Michael NAVARRO (840 United States of America), Oleksandr PLATOSHYN (840 United States of America), Andreas N. GLUD (840 United States of America), Silvia MARSALA (840 United States of America), Jozef KAFKA (840 United States of America), Atsushi MIYANOHARA (840 United States of America), Tomohisa KATO JR. (392 Japan), Takahiro TADOKORO (840 United States of America), Michael P. HEFFERAN (840 United States of America), Kota KAMIZATO (840 United States of America), Tetsuya YOSHIZUMI (840 United States of America), Stefan JUHAS (203 Czech Republic), Jana JUHASOVA (203 Czech Republic), Chak-Sum HO (840 United States of America), Taba KHERADMAND (840 United States of America), PeiXi CHEN (840 United States of America), Dáša BOHAČIAKOVÁ (703 Slovakia, belonging to the institution), Marian HRUSKA-PLOCHAN (840 United States of America), Andrew J. TODD (826 United Kingdom of Great Britain and Northern Ireland), Shawn P. DRISCOLL (840 United States of America), Thomas D. GLENN (840 United States of America), Samuel L. PFAFF (840 United States of America), Jiri KLIMA (203 Czech Republic), Joseph CIACCI (840 United States of America), Eric CURTIS (840 United States of America), Fred H. GAGE (840 United States of America), Jack BUI (840 United States of America), Kazuhiko YAMADA (840 United States of America), Alysson R. MUOTRI (840 United States of America) and Martin MARSALA (840 United States of America, guarantor)

Edition

Science Translational Medicine, Washington, American Association for the Advancement of Science, 2018, 1946-6234

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 17.200

RIV identification code

RIV/00216224:14110/18:00102732

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1126/scitranslmed.aam6651

UT WoS

000431766400001

Keywords in English

cells derived; iPSC

Tags

14110517, EL OK, rivok

Tags

International impact, Reviewed
Změněno: 10/2/2019 19:54, Soňa Böhmová

Abstract

V originále

The use of autologous (or syngeneic) cells derived from induced pluripotent stem cells (iPSCs) holds great promise for future clinical use in a wide range of diseases and injuries. It is expected that cell replacement therapies using autologous cells would forego the need for immunosuppression, otherwise required in allogeneic transplantations. However, recent studies have shown the unexpected immune rejection of undifferentiated autologous mouse iPSCs after transplantation. Whether similar immunogenic properties are maintained in iPSC-derived lineage-committed cells (such as neural precursors) is relatively unknown. We demonstrate that syngeneic porcine iPSC-derived neural precursor cell (NPC) transplantation to the spinal cord in the absence of immunosuppression is associated with long-term survival and neuronal and glial differentiation. No tumor formation was noted. Similar cell engraftment and differentiation were shown in spinally injured transiently immunosuppressed swine leukocyte antigen (SLA)–mismatched allogeneic pigs. These data demonstrate that iPSC-NPCs can be grafted into syngeneic recipients in the absence of immunosuppression and that temporary immunosuppression is sufficient to induce long-term immune tolerance after NPC engraftment into spinally injured allogeneic recipients. Collectively, our results show that iPSC-NPCs represent an alternative source of transplantable NPCs for the treatment of a variety of disorders affecting the spinal cord, including trauma, ischemia, or amyotrophic lateral sclerosis.
Displayed: 25/12/2024 11:18